Cholesterol metabolism and lethal prostate cancer

Konrad H. Stopsack, Travis A. Gerke, Jennifer A. Sinnott, Kathryn L. Penney, Svitlana Tyekucheva, Howard D. Sesso, Swen-Olof Andersson, Ove Andrén, James R. Cerhan, Edward L. Giovannucci, Lorelei A. Mucci, Jennifer R. Rider


Cholesterol metabolism has been implicated in prostate cancer pathogenesis. Here, we assessed the association of intratumoral mRNA expression of cholesterol synthesis enzymes, transporters, and regulators in tumor specimen at diagnosis and lethal prostate cancer, defined as mortality or metastases from prostate cancer in contrast to nonlethal disease without evidence of metastases after at least 8 years of follow-up. We analyzed the prospective prostate cancer cohorts within the Health Professionals Follow-up Study (n = 249) and the Physicians’ Health Study (n = 153) as well as expectantly managed patients in the Swedish Watchful Waiting Study (n = 338). The expression of squalene monooxygenase (SQLE) was associated with lethal cancer in all three cohorts. Men with high SQLE expression (>1 standard deviation above the mean) were 8.3 times (95% confidence interval, 3.5 to 19.7) more likely to have lethal cancer despite therapy compared with men with the mean level of SQLE expression. Absolute SQLE expression was associated with lethal cancer independently from Gleason grade and stage, as was a SQLE expression ratio in tumor versus surrounding benign prostate tissue. Higher SQLE expression was tightly associated with increased histologic markers of angiogenesis. Collectively, this study establishes the prognostic value of intratumoral cholesterol synthesis as measured via SQLE, its second rate-limiting enzyme. SQLE expression at cancer diagnosis is prognostic for lethal prostate cancer both after curative-intent prostatectomy and in a watchful waiting setting, possibly by facilitating micrometastatic disease.

Published In Cancer Research
Date Aug 1, 2016
DOI 10.1158/0008-5472.CAN-16-0903


Stopsack KH, Gerke TA, Sinnott JA, Penney KL, Tyekucheva S, Sesso HD, Andersson S, Andrén O, Cerhan JR, Giovannucci EL, Mucci LA, Rider JR. Cholesterol metabolism and lethal prostate cancer. Cancer Res 2016; 76(16): 4785--4790. PMID: 27325648. PMCID: PMC4987257.